News & Analysis on Clinical Trial Services & Contract Research And Development
A consortium of researchers has detailed the activity of a novel drug compound that kills multiple HIV strains via a unique mechanism of action. The discovery brings with it hope in using this compound in both topical and systemic applications for HIV...
A unique DNA-based targeting technology has shown to halt tumour progression with significantly smaller chemotherapy doses opening the way to reduce the side effects as well as increase the efficacy of anti cancer therapies.
Asynt have launched the first affordable 500ml parallel reactor on the market with its latest addition to the DrySyn range, providing a safe and flexible alternative to oil bath and mantles.
Chiltern is expanding its clinical trial services business in India, and in doing so will be the first company to provide specialised staff recruitment services for the Indian clinical research industry.
2005 was a good year for PPD. With a 32 per cent jump in profit thanks to a better-than-expected 23 per cent rise in net revenue to $1.037bn (€800m).
Swiss pharma giants, Novartis has formed a collaboration with Alnylam, which aims to develop an RNAi-based therapeutic for pandemic flu. The deal is in response to analysts who believe that current vaccines and existing anti-viral agents may not be...
A natural compound could become the starting molecule for the design of drugs that prolongs lifespan and delay the onset of aging-related traits in vertebrate organisms, supporting the potential utility of the compound in human aging research.